Clinical trials: Oncologic
Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer
xDRIVE in Metastatic Colorectal Cancer
The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC).
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer, Metastatic Rectal Adenocarcinoma, Metastatic Rectal Carcinoma
- Trial name
- NCT06929338
- Testing
- Functional precision medicine
- Sponsor
- First Ascent Biomedical Inc.
Relapsed or Refractory Multiple Myeloma
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
- Trial name
- NCT03512353
- Testing
- Dexamethasone, Carfilzomib
- Where
- 31 sites in United States
- Volunteers
- 7 people
- Sponsor
- Amgen
Leukemia, Myeloid, Chronic-Phase
Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting
This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment…
- Trial name
- NCT07374120
- Where
- United States
- Volunteers
- 1,480 people
- Sponsor
- Novartis Pharmaceuticals
Febrile Neutropenia, Neutropenia
Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients
Febrile neutropenia (FN) is a major life-threatening treatment complication in cancer patients undergoing intensive chemotherapy. Endogenous flora is considered to be one of the main sources of infections during neutropenia.
- Conditions
- Febrile Neutropenia, Neutropenia, Infection in an Immunocompromised Host, Cancer
- Trial name
- FENSY (NCT02544685)
- Testing
- Probio-Fix Inum, Beneo Synergy 1
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- S&D Pharma SK s.r.o.
Myelodysplastic Syndromes (MDS)
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Alvocidib, a cyclin-dependent kinase 9 (CDK 9) inhibitor, in time-sequential therapy demonstrated significant clinical activity in secondary AML patients with prior MDS.
- Trial name
- NCT03593915
- Testing
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sumitomo Pharma America, Inc.
Colorectal Cancer, Epithelial Ovarian Cancer
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer…
- Conditions
- Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma
- Trial name
- NCT07432633
- Testing
- [18F]FPyQCP
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Blue Earth Diagnostics
Advanced Solid Tumor
A Study of YL242 in Subjects With Advanced Solid Tumors
This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.
- Trial name
- NCT07197827
- Testing
- YL242, YL242; Pembrolizumab, YL242; 5-FU; LV
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 424 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Colorectal Neoplasm
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
- Trial name
- NCT03384940
- Testing
- DS-8201a
- Where
- 25 sites in United States, Italy and 3 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Breast Cancer, Urine
Investigation of Urinary Biomarkers for the Detection of Breast Cancer
The aim of this study is to investigate and possibly validate urinary biomarkers for breast cancer. During this study the focus will be on aberrations of selected genes as prognostic or predictive value has been shown for these…
- Conditions
- Breast Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP3 (NCT05453591)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novosanis NV
Chronic Lymphocytic Leukemia
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling…
- Trial name
- NCT02141282
- Testing
- Venetoclax
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- AbbVie
Ovarian Cancer, Fallopian Tube Cancer
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)
Patients enrolled into this study will be stratified into 3 groups based on gene mutations identified in their tumor tissue. The purpose of this study is to evaluate patient response to maintenance treatment with rucaparib versus…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL3 (NCT01968213)
- Testing
- Rucaparib
- Where
- 96 sites in United States, Australia and 9 more
- Volunteers
- 564 people
- Sponsor
- pharmaand GmbH
Cancer
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
JTX-2011-201 is a Phase 2, open label clinical study of vopratelimab (JTX-2011) and ipilimumab in adult subjects with non-small cell lung cancer (NSCLC) or urothelial cancer to evaluate safety and efficacy.
- Trial name
- EMERGE (NCT03989362)
- Testing
- Vopratelimab, Ipilimumab
- Where
- 21 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Jounce Therapeutics, Inc.
Advanced Malignancies
Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors
This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in cancer subjects who failed standard treatment.
- Trial name
- NCT04328831
- Testing
- IBI322
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Select Advanced Solid Tumors
A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.
- Trial name
- NCT02705482
- Testing
- MEDI0562, Tremelimumab, Durvalumab
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 58 people
- Sponsor
- MedImmune LLC
Metastatic Castration Resistant Prostate Cancer (mCRPC)
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
This was an open-label Phase 1b/2 study involving oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration-Resistant Prostate Cancer.
- Trial name
- NCT03480646
- Testing
- CPI-1205, Cobicistat, Enzalutamide
- Where
- 41 sites in United States
- Volunteers
- 175 people
- Sponsor
- Constellation Pharmaceuticals
Colorectal Cancer
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
- Trial name
- NCT02785068
- Testing
- MM-151, nal-IRI, Leucovorin
- Sponsor
- Merrimack Pharmaceuticals
Advanced Cancer
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
- Trial name
- FRACTION-RCC (NCT02996110)
- Testing
- Nivolumab, Ipilimumab, Relatlimab
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Castration-resistant Prostate Cancer
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
- Trial name
- NCT06691984
- Testing
- Xaluritamig, Abiraterone, Enzalutamide
- Where
- 164 sites in United States, Australia and 20 more
- Volunteers
- 707 people
- Sponsor
- Amgen
Advanced Non Small Cell Lung Cancer
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended…
- Trial name
- NCT03326752
- Testing
- DV281, Breath Actuated Nebulizer, DV281 (RP2D)
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dynavax Technologies Corporation
Metastatic Uveal Melanoma in the Liver
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
- Trial name
- NCT04935229
- Testing
- SD-101, Nivolumab, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- TriSalus Life Sciences, Inc.